Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ? 50%: EMPOWER-Lung 1 subgroup analysis. için istatistikler
Toplam ziyaret
| views | |
|---|---|
| Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ? 50%: EMPOWER-Lung 1 subgroup analysis. | 0 |
Aylık toplam ziyaret
| views | |
|---|---|
| Aralık 2024 | 0 |
| Ocak 2025 | 0 |
| Şubat 2025 | 0 |
| Mart 2025 | 0 |
| Nisan 2025 | 0 |
| Mayıs 2025 | 0 |
| Haziran 2025 | 0 |
